Retour aux projets

19080.2 PFLS-LS

Selective small molecule LFA-1 inhibitors to restore self-protective immune privilege in non-infectious posterior uveitis.

Résumé

Selective small molecule LFA-1 inhibitors to restore self-protective immune privilege in non-infectious posterior uveitis.

Textes supplémentaires

Abstract

Non-infectious posterior uveitis is a sight-threatening inflammatory eye disease which accounts for 10% of preventable blindness, despite currently available therapies. There is a high need for medications which not only provide sight-saving efficacy yet also lasting protection against disease. The goal of this project is to advance such potential therapy, a newly discovered class of small molecule compounds selectively inhibiting the integrin lymphocyte function-associated antigen-1 (LFA-1), to pre-clinical proof-of concept (PoC) and drug candidate status. The current project is expected to be followed by toxicology studies enabling clinical entry and subsequent clinical exploration of an innovative sight-saving regimen, aiming to restore the eyes natural immune privilege for potential freedom of disease.

Participants

Albrecht-Georg Schmidt

Wirtschaftspartner

albrecht.schmidt@allocyte-pharma.com

AlloCyte Pharmaceuticals AG Albrecht-Georg Schmidt Hochbergerstrasse 60C 4057 Basel BS CH

Daniel Gygax

Kontaktperson

daniel.gygax@fhnw.ch

FHNW Fachhochschule Nordwestschweiz Hochschule für Life Sciences Daniel Gygax Gründenstrasse 40 4132 Muttenz BL CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2016-09-30
Date de fin
2018-10-31
Coûts totaux approuvés
CHF 395320.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%